Kuros reports Corporate Highlights as of Q1 2024 including increase in direct MagnetOsTM sales
Financial Highlights Direct MagnetOs sales rose by 155% to CHF 13.9 million in Q1 2024 from CHF 5.4 million in Q1 2023…
Financial Highlights Direct MagnetOs sales rose by 155% to CHF 13.9 million in Q1 2024 from CHF 5.4 million in Q1 2023…
Kuros Biosciences (SIX:KURN), a leader in next generation bone graft technologies, held its Annual General Meeting today…
Außen Xive – innen konisch. So lässt sich das OmniTaper EV-Implantat kurz am besten beschreiben. Durch die Kombination d…
Financial highlights Direct MagnetOs sales grew by 163% to CHF 31.7 million in 2023, climbing from CHF 12.1 million…
Europäisches Design und hohe Verarbeitungsqualität sind Kernelemente der Marke Philips und wichtige Aspekte für die Att…
EVA Pharma, one of the fastest-growing pharmaceutical companies in the Middle East and Africa (MEA), has recently celebr…
“Those who have worn the HoloLens 2 in the operating room see it as a true game-changer. They have the planning images i…
Kuros Biosciences (“Kuros” or “the Company”), a leader in next generation bone graft technologies, today announced it wi…
MagnetOs™ Granules becomes the third product in the MagnetOs portfolio to receive FDA clearance to market for inter…
Axiom X3® TL ist das neueste Implantat der Axiom®-Reihe von Anthogyr, einem französischen Unternehmen der Straumann Grou…